TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03452267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral, 850 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: oral, 45 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, once daily
Study: NCT04294485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Electrostimulation combined with exercise
Study: NCT00484315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
Description: TAXUS Element stent placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
Description: TAXUS Express Stent Implant
Study: NCT02344576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DT LVAD Decision Support Intervention
Description: Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
Study: NCT02022826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill Monitoring System
Study: NCT03306654

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study: NCT04334382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight \< 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of \>20.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
Study: NCT00748657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04523740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
Study: NCT00730340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the Tonsillar Fossa
Description: We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy with open fossa
Description: SOP for a tonsillectomy.
Study: NCT03140319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblast
Description: Transplantation of 20 million cell by three injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of Placebo
Study: NCT02210338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz C-MAC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils Intubation Fibrescope
Study: NCT03170830

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: the diagnosis value of cUck2 in acute myocardial infarction.
Description: Collect blood at different time points and compare cUck2 in three groups.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: the diagnosis value of cUck2 in acute myocardial infarction.
Description: Collect blood at different time points and compare cUck2 in three groups.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: the diagnosis value of cUck2 in acute myocardial infarction.
Description: Collect blood at different time points and compare cUck2 in three groups.
Study: NCT01856114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet
Description: Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Buccal Tablet
Description: Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
Study: NCT01245673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar- Pneumococcal Conjugate Vaccine (PCV)
Description: After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
Study: NCT03726450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Myo-inositol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: N-Acetyl-Cysteine
Study: NCT01245673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated/costimulated autologous T-cell
Description: For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion \~day 2 post-transplant. The target number of costimulated T-cells for infusion will be \~ 5 x 10e10 T-cells total in 100-500 mL total volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlamid® (Lenalidomide)
Description: At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
Study: NCT03726450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Folic Acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Selenium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: L-arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: L-carnitine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Vitamin E
Study: NCT02980952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Forearm immobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm immobilization
Study: NCT03995251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Supplementation
Description: Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise
Study: NCT02516540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training plus mediterranean diet
Description: Structured exercise training plus mediterranean diet
Study: NCT02108340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave radiometry
Description: Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
Study: NCT00660881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
Study: NCT00955305

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT05949034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL E-Cigarette Device
Description: We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL E-Cigarette Device
Description: We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL E-Cigarette Device
Description: We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
Study: NCT02624947

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F vaccine with adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Formulation buffer
Study: NCT00956098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oltipraz
Description: 60mg bid 90mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00588159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
Study: NCT01245673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Description: After study enrollment, patients will receive both MAGE-A3/GM-CSF \[+ coinjection of 2mg of Hiltonol®(Poly-ICLC)\]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
Study: NCT00355121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
Study: NCT04531384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted rehabilitation intelligent treatment
Description: robot-assisted rehabilitation psychotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: standard psychotherapy treatment
Description: standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
Study: NCT01796002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin + CHOP
Description: Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
Study: NCT03541473

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptamen® 1.5 Vanilla
Description: Nutritionally complete formula with 10g MCT in 250 mL, commercially available

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Boost Plus® Vanilla
Description: Product of same nutritional composition but without MCT
Study: NCT03114449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture with indwelling fixed needles at specific AA points

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupuncture
Description: Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
Study: NCT04011202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality gaming program (VR-gaming program)
Description: Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
Study: NCT02617355

Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype surgical magnetic drape
Description: New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax

Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype surgical magnetic drape
Description: New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax

Intervention type: DEVICE
Group type: OTHER
Intervention: Green Covidien Magnetic Drape
Description: Green Covidien Magnetic Drape applied to the patient's thorax

Intervention type: DEVICE
Group type: OTHER
Intervention: Green Covidien Magnetic Drape
Description: Green Covidien Magnetic Drape applied to the patient's thorax

Intervention type: DEVICE
Group type: OTHER
Intervention: Jac-Cell Medic Reusable Magnetic Pad
Description: Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
Study: NCT01221922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RevLite Q-Switched Nd:YAG Laser
Description: Laser treatment once every 2 weeks for a total of 10 treatments.
Study: NCT01316549

Intervention type: DRUG
Intervention: Fludarabine
Description: Given as injection
Study: NCT05345236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal (IVT) injection
Study: NCT01530620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride ER (extended release)
Description: 45 mg capsule (1x1/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propiverine hydrochloride IR (immediate release)
Description: 15 mg tablet (3x1/d)
Study: NCT04577846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin 500 MG
Description: Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
Study: NCT01313273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide, non steroidal anti androgens and LHRH-a
Description: Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression.

Intervention type: DRUG
Group type: OTHER
Intervention: Non steroidal anti androgens and LHRH-a
Description: Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
Study: NCT03879915

Intervention type: PROCEDURE
Intervention: Dental Implant placement
Description: Surgical placement of dental implant not associated with prior or concurrent bone augmentation

Intervention type: PROCEDURE
Intervention: Dental Implant placement
Description: Surgical placement of dental implant not associated with prior or concurrent bone augmentation
Study: NCT03957239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry Beverage
Description: The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Beverage
Description: The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).
Study: NCT03269409

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lactated Ringers
Description: Approximately 5 mls of lactated ringers will be injected after decompression into the hip that does not receive adipose derived regenerative cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Celution 800/GP System (Cytori Therapeutics)
Description: The Celution 800/GP System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose Derived Regenerative Cells (ADRC)
Description: Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
Study: NCT02613260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT Outreach
Description: This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
Study: NCT04615793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILATES EXERCISES
Description: The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
Study: NCT00614471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg po daily from week 13 to week 36

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week from week 21 to week 68
Study: NCT03352271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Incremental hemodialysis
Description: Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thrice weekly hemodialysis
Description: Thrice weekly hemodialysis program, the current standard of care for all patients, as a control